Publication:
The role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal

dc.contributor.coauthorJafarova Demirkapu, Mahluga
dc.contributor.coauthorYananlı, Hasan Raci
dc.contributor.coauthorKaleli, Melisa
dc.contributor.coauthorSakallı, Halil Eren
dc.contributor.coauthorGören, Mehmet Zafer
dc.contributor.departmentN/A
dc.contributor.kuauthorTopkara, Betilay
dc.contributor.kuprofilePhD Student
dc.contributor.schoolcollegeinstituteGraduate School of Health Sciences
dc.contributor.yokid353320
dc.date.accessioned2024-11-09T23:43:42Z
dc.date.issued2020
dc.description.abstractOpioids are effective analgaesic agents, but serious adverse effects such as tolerance and withdrawal contribute to opioid dependence and limit their use. Opioid withdrawal is a common occurrence in human opiate addicts that is not life-threatening. Studies have shown that the mesocorticolimbic system, especially the nucleus accumbens, is an important region in drug addiction and adenosine receptors play a modulatory role in the mechanism of action of drug dependence and withdrawal. The aim of this study was to investigate the effects of the selective A1 receptor agonist CPA (N6-cyclopentyladenosine) on withdrawal symptoms, and the concentration of dopamine and noradrenaline in the nucleus accumbens and locomotor activity behaviour during naloxone-precipitated withdrawal in morphine-dependent rats. The local administration of CPA (1.5, 3.0, and 6.0 mmol/L bilateral 250 nL) into the nucleus accumbens decreased the Gellert–Holtzman withdrawal scale, and increased concentrations of dopamine and noradrenaline in the same region during naloxone-induced withdrawal. Our findings suggest that administration of the A1 receptor agonist significantly decreased withdrawal behaviours and increased dopamine and noradrenaline concentrations in opioid withdrawal in a dose-dependent manner. These results demonstrate that adenosine receptors should be examined as a potential mechanism that could be exploited for the treatment of morphine withdrawal. 
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume47
dc.identifier.doi10.1111/1440-1681.13224
dc.identifier.eissn1440-1681
dc.identifier.issn0305-1870
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85080836371
dc.identifier.urihttp://dx.doi.org/10.1111/1440-1681.13224
dc.identifier.urihttps://hdl.handle.net/20.500.14288/13540
dc.identifier.wos508566100001
dc.keywordsAdenosine
dc.keywordsCPA
dc.keywordsDopamine
dc.keywordsMorphine
dc.keywordsNoradrenaline
dc.keywordsNucleus accumbens
dc.languageEnglish
dc.sourceClinical and Experimental Pharmacology and Physiology
dc.subjectPharmacology
dc.titleThe role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-3509-9296
local.contributor.kuauthorTopkara, Betilay

Files